Jazz Pharmaceuticals has priced an upsized private offering of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032, up from the previously announced $1 billion. The notes will accrue interest semiannually at 1.875% per year, with payments beginning March 15, 2027, and will mature on September 15, 2032, unless earlier exchanged, redeemed, or repurchased. The company has also granted initial purchasers an option to buy up to an additional $150 million in notes within 13 days from the issue date. The sale is expected to close on August 31, 2026, and the stock closed down 4% on Wednesday.
Jazz Pharmaceuticals PLCPriced upsized $1.1B debt offering, stock closed down 4%
